Cancer Prevention Initiative Inc is located in Dallas, TX. The organization was established in 2015. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Cancer Prevention Initiative Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Cancer Prevention Initiative Inc generated $151.0 in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (70.6%) each year. All expenses for the organization totaled $308.0k during the year ending 12/2021. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
CANCER PREVENTION INITIATIVE, INC. (CPI) IS A NONPROFIT CORPORATION WHOSE MISSION IS TO ACCELERATE THE DISCOVERY AND DEVELOPMENT OF NEW MEDICINES THAT PREVENT CANCER.
Describe the Organization's Program Activity:
Part 3 - Line 4a
IN 2021, THE CANCER PREVENTION INITIATIVE (CPI) PROGRAMS HAVE PROGRESSED AND CPI CONTINUES TO GROW AND DEVELOP. CPI'S RESEARCH GRANT RECIPIENTS HAVE CONTINUED TO ADVANCE US TOWARDS UNDERSTANDING AND PREVENTING INHERITED CANCERS. A NEWLY FUNDED PROJECT WITH CLEVELAND CLINIC SEEKS TO IDENTIFY PROTEINS UNIQUELY AND HIGHLY EXPRESSED IN BREAST CANCER OF BRCA1 MUTATION CARRIERS. IDENTIFICATION OF THESE UNIQUE PROTEINS IS AN IMPORTANT LINK FOR DEVELOPING PREVENTATIVE VACCINES. ALSO NEWLY FUNDED IS A PROJECT WITH MEMORIAL SLOAN KETTERING CANCER CENTER TO GENERATE A ROBUST CELLULAR ASSAY THAT WOULD ALLOW FOR THE SCREENING OF HUNDREDS OF COMPOUNDS TO IDENTIFY DETERMINANTS OF LOSS OF HETEROZYGOSITY (LOH) OF BRCA GENES. LOH IS A MAJOR DRIVER IN CANCER INITIATION, AND DISCOVERY OF COMPOUNDS THAT CAUSE LOH CAN BE KEY FOR PREVENTION DISCOVERIES. ONGOING PROJECTS INCLUDE HARVARD'S BETH ISRAEL DEACONESS MEDICAL CENTER WHERE THEY ARE WORKING TO IDENTIFY CANCER RISK PREDICTORS IN THE REPRODUCTIVE EPITHELIUM IN BRCA MUTATION CARRIERS. A PROJECT AT CITY OF HOPE IS PROGRESSING TO REPURPOSE A SAFE, FDA APPROVED ANTI-PARASITIC DRUG THAT HAS GREAT PROMISE FOR REDUCING BREAST CANCER GROWTH. REPURPOSING DRUGS IS A SAFE WAY TO BRING THERAPIES TO PATIENTS QUICKLY. RELATED TO THIS IS A NEED FOR WAYS TO EVALUATE KNOWN DRUGS FOR NEW PURPOSES. A TEAM AT THE UNIVERSITY OF TORONTO IS DEVELOPING A TEST TO SCREEN FOR DRUGS THAT CAN RESTORE NORMAL BRCA1 FUNCTION TO BRCA1 DEFICIENT CELLS. AN INTERNATIONAL COLLABORATION HAS CO-DEVELOPED A CANDIDATE VACCINE FOR THE PREVENTION OF TRIPLE NEGATIVE BREAST CANCERS IN PATIENTS WHO HAVE INHERITED A BRCA1 MUTATION. NEW GRANTS WERE MADE IN 2021 TOTALED $480,000. THIS AMOUNT IS OFFSET BY THE RETURN OF $264,764 FROM A 2017 GRANT WHERE THE GRANTEE WAS NOT ABLE TO COMPLETE THEIR CONTRACTED PROJECT. THE GRANT EXPENSES FOR 2021 ARE $480,000 - 264,764 = $215,236.
EDUCATION AND COMMUNITY ENGAGEMENT PROGRAMS: AS WE MOVE CLOSER TO OUR GOAL OF ERADICATING ALL CANCERS THROUGH PREVENTATIVE MEDICINES, WE BELIEVE THAT EDUCATING THE PUBLIC AND RAISING AWARENESS ABOUT INHERITED CANCER SYNDROMES WILL INSPIRE MORE INDIVIDUALS TO TAKE PROACTIVE, LIFE-SAVING PREVENTIVE MEASURES. ONE OF THE GOALS IS TO ENHANCE THE SCIENTIFIC REACH OF THE ORGANIZATION AND RAISE AWARENESS ON CANCER PREVENTION TO A BROADER AUDIENCE OF PATIENTS, ADVOCATES AND DONORS. THUS, REGULAR UPDATES ON SCIENTIFIC AND MEDICAL RESEARCH ADVANCES, RECENT CLINICAL TRIALS, AND INTERVIEWS WITH EXPERTS IN CANCER PREVENTION ARE PUBLISHED ON WEB-BASED PLATFORMS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Theodora Ross President & Chief Scientific Officer | OfficerTrustee | 10 | $50,000 |
Kirk Patrick Secretary | OfficerTrustee | 0.5 | $0 |
Howard Janzen Board Chair; Chief Financial Officer | Trustee | 3 | $0 |
Joi Morris Trustee | Trustee | 5 | $0 |
Jan Livingston-Mokhtari Trustee | Trustee | 0.5 | $0 |
Douglas Hager Trustee, Sr. Vice President, Project Management And Operations | Trustee | 10 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $135 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $135 |
Total Program Service Revenue | $0 |
Investment income | $16 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $151 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $215,236 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $50,000 |
Compensation of current officers, directors, key employees. | $0 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $0 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $0 |
Payroll taxes | -$84 |
Fees for services: Management | $0 |
Fees for services: Legal | $0 |
Fees for services: Accounting | $23,539 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $1,703 |
Fees for services: Other | $0 |
Advertising and promotion | $0 |
Office expenses | $4,234 |
Information technology | $5,837 |
Royalties | $0 |
Occupancy | $0 |
Travel | $0 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $3,590 |
Insurance | $2,246 |
All other expenses | $0 |
Total functional expenses | $308,042 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $3,894 |
Savings and temporary cash investments | $82,786 |
Pledges and grants receivable | $25,000 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $6,414 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $832,402 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $12,175 |
Other assets | $0 |
Total assets | $962,671 |
Accounts payable and accrued expenses | $938 |
Grants payable | $500,358 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $501,296 |
Net assets without donor restrictions | $171,611 |
Net assets with donor restrictions | $289,764 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $962,671 |
Over the last fiscal year, Cancer Prevention Initiative Inc has awarded $480,000 in support to 3 organizations.
Grant Recipient | Amount |
---|---|
Dallas, TX PURPOSE: Scientific and administrative oversight of all Cancer Prevention Initiative programs. | $180,000 |
Independence, OH PURPOSE: The objective of this project is to identify proteins uniquely and highly expressed in breast cancer of BRCA1 mutation carriers. Identification of these proteins can be key to developing preventative vaccines. | $150,000 |
New York, NY PURPOSE: The objective of this project is to generate a robust cellular assay that would allow for the screening of hundreds of compounds to identify determinants of Loss of Heterozygosity (LoH) of BRCA genes. LoH is a major driver in cancer initiation. | $150,000 |
Over the last fiscal year, we have identified 1 grants that Cancer Prevention Initiative Inc has recieved totaling $250,000.
Awarding Organization | Amount |
---|---|
Greater Horizons Kansas City, MO PURPOSE: Medical Research | $250,000 |
Organization Name | Assets | Revenue |
---|---|---|
Louisiana Cancer Research Center Of Lsu Health Sciences Center In No New Orleans, LA | $132,139,228 | $19,291,637 |
Mary Crowley Medical Research Center Dallas, TX | $12,682,772 | $12,969,908 |
Moncrief Cancer Foundation Dallas, TX | $110,245,526 | $7,934,039 |
Cll Global Research Foundation Houston, TX | $12,430,009 | $2,747,960 |
Childrens Cancer Fund Of New Mexico Albuquerque, NM | $4,201,839 | $793,294 |
Mothers Against Cancer Inc Kingwood, TX | $433,566 | $683,347 |
Childrens Cancer Fund Of Dallas Inc Dallas, TX | $1,063,964 | $471,385 |
Texas Oncology Foundation Inc Dallas, TX | $2,137,196 | $1,014,114 |
Hope Hits Harder New Braunfels, TX | $862,674 | $658,187 |
The Carmage And Martha Ann Walls Foundation Houston, TX | $5,135,890 | $343,509 |
Acadiana Medical Research Foundation Inc Lafayette, LA | $774,653 | $351,957 |
Society For Melanoma Research Ltd Albuquerque, NM | $2,765,430 | $368,576 |